Lurtotecan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Lurtotecan
Accession Number
DB12222
Type
Small Molecule
Groups
Investigational
Description

Lurtotecan is under investigation in clinical trial NCT00022594 (Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
4J1L80T08I
CAS number
149882-10-0
Weight
Average: 518.57
Monoisotopic: 518.216534702
Chemical Formula
C28H30N4O6
InChI Key
RVFGKBWWUQOIOU-NDEPHWFRSA-N
InChI
InChI=1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
IUPAC Name
(18S)-18-ethyl-18-hydroxy-2-[(4-methylpiperazin-1-yl)methyl]-6,9,20-trioxa-13,24-diazahexacyclo[12.11.0.0^{3,12}.0^{5,10}.0^{15,24}.0^{17,22}]pentacosa-1(14),2,4,10,12,15,17(22)-heptaene-19,23-dione
SMILES
CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C4OCCOC4=CC1=C3CN1CCN(C)CC1)C2=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lurtotecan.
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Lurtotecan.
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Lurtotecan.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lurtotecan.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lurtotecan.
CymarinCymarin may decrease the cardiotoxic activities of Lurtotecan.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lurtotecan.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lurtotecan.
DigoxinDigoxin may decrease the cardiotoxic activities of Lurtotecan.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lurtotecan.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
60956
PubChem Substance
347828501
ChemSpider
54919
BindingDB
50036130
ChEMBL
CHEMBL305666
Wikipedia
Lurtotecan

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.713 mg/mLALOGPS
logP1.66ALOGPS
logP0.52ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)11.71ChemAxon
pKa (Strongest Basic)7.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area104.67 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity140.04 m3·mol-1ChemAxon
Polarizability56.18 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Camptothecins
Sub Class
Not Available
Direct Parent
Camptothecins
Alternative Parents
Quinolines and derivatives / Pyranopyridines / Benzo-1,4-dioxanes / Alkyl aryl ethers / Pyridinones / Aralkylamines / N-methylpiperazines / Para dioxins / Benzenoids / Tertiary alcohols
show 13 more
Substituents
Camptothecin / Quinoline / Benzo-1,4-dioxane / Benzodioxane / Pyranopyridine / Alkyl aryl ether / Pyridinone / N-methylpiperazine / N-alkylpiperazine / Aralkylamine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:39 / Updated on August 02, 2018 06:35